Compare LCTX & CMRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCTX | CMRC |
|---|---|---|
| Founded | 1990 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 393.9M | 399.0M |
| IPO Year | N/A | 2020 |
| Metric | LCTX | CMRC |
|---|---|---|
| Price | $1.68 | $4.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $4.25 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 1.3M | 645.0K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $10,816,000.00 | ★ $339,860,000.00 |
| Revenue This Year | $5.24 | $5.15 |
| Revenue Next Year | $126.78 | $4.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.05 | 2.97 |
| 52 Week Low | $0.37 | $4.14 |
| 52 Week High | $2.09 | $7.69 |
| Indicator | LCTX | CMRC |
|---|---|---|
| Relative Strength Index (RSI) | 46.00 | 36.97 |
| Support Level | $1.69 | $4.46 |
| Resistance Level | $1.79 | $4.61 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 43.75 | 2.88 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Commerce.com Inc is engaged in offering Software-as-a-service (SaaS) e-commerce platform. The company's SaaS platform engages in the creation of online stores by delivering a combination of ease-of-use, enterprise functionality, and flexibility. It powers both the customers' branded ecommerce stores and their cross-channel connections to popular online marketplaces, social networks, and offline point-of-sale systems. The group operates in a single segment covering geographical areas of Americas-U.S.; Americas-other; EMEA; and APAC, of which majority of its revenue is generated from Americas-U.S.